There’s a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on Accenture (ACN – Research Report), Phunware (PHUN – Research Report) and Health Catalyst (HCAT – Research Report) with bullish sentiments.
Accenture (ACN)
According to TipRanks.com, Shirvaikar is a 4-star analyst with an average return of
Accenture has an analyst consensus of Moderate Buy, with a price target consensus of $310.00, implying a 19.5% upside from current levels. In a report issued on March 13, Bank of America Securities also maintained a Buy rating on the stock with a $350.00 price target.
See today’s best-performing stocks on TipRanks >>
Phunware (PHUN)
In a report released today, Scott Buck from H.C. Wainwright maintained a Buy rating on Phunware, with a price target of $2.50. The company’s shares closed last Thursday at $0.74.
According to TipRanks.com, Buck is ranked 0 out of 5 stars with an average return of
Phunware has an analyst consensus of Moderate Buy, with a price target consensus of $2.63.
Health Catalyst (HCAT)
According to TipRanks.com, Grosslight is a 4-star analyst with an average return of
Currently, the analyst consensus on Health Catalyst is a Moderate Buy with an average price target of $15.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACN:
